INCB 50465

Drug Profile

INCB 50465

Alternative Names: INCB-050465; INCB-50465

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Myelofibrosis
  • Phase I/II B cell lymphoma; Solid tumours
  • Phase I Follicular lymphoma

Most Recent Events

  • 11 May 2017 Incyte Corporation plans the CITADEL-204 phase II trial for MALT-lymphoma (NCT03144674)
  • 27 Apr 2017 Incyte Corporation plans the CITADEL-203 phase II trial for Follicular lymphoma (Second-line therapy or greater) in USA (NCT03126019)
  • 02 Apr 2017 Pharmacodynamics data from a preclinical trial in Diffuse large B cell lymphoma presented at the 108th Annual Meeting of the American Association for Cancer Research(AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top